Trevi Therapeutics (TRVI) Tops Q2 EPS by 2c

Trevi Therapeutics (NASDAQ: TRVI) reported Q2 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• ServiceNow (NOW) PT Raised to $155 at Needham
• KeyBanc Starts Oiln (OLN) at Overweight